Abstract
The accuracy of modern imaging techniques for the diagnosis of peritoneal carcinomatosis is poor. A breast cancer patient with a high serum CA15-3 level did not receive a definitive diagnosis of peritoneal dissemination by imaging examination and then underwent laparoscopy. Pathological examination showed peritoneal dissemination of breast cancer, but the biological markers were different from the primary lesion: ER(−), PgR(−), and Her2:3 +. T-DM1 therapy was very effective, and her systemic symptoms disappeared. Since biomarkers of metastatic lesions may sometimes change, laparoscopic biopsy is very important and useful.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Breast cancer is the most common cancer in women and can metastasize to many organ sites. In particular, peritoneal dissemination from breast cancer is uncommon and a life-threatening condition with a very high mortality rate. It has always been managed by systemic chemotherapy, exclusively with palliative intent. Moreover, the accuracy of modern imaging techniques for the diagnosis of peritoneal carcinomatosis is poor. The case of a patient with peritoneal dissemination from breast cancer diagnosed by laparoscopy is presented in which the biomarkers differed from those of the primary lesion on pathological examination, which could be very useful information for subsequent systemic treatment.
Case report
A 68-year-old woman was diagnosed with left early breast cancer and underwent partial resection and sentinel lymph node biopsy. The pathological findings were as follows: T1cN0M0, invasive ductal carcinoma (papillotubular carcinoma), nuclear grade: 3, ER(+), PgR(−), and HER2:0. Adjuvant chemotherapy consisted of 4 cycles of EC (epirubicin and cyclophosphamide), and adjuvant hormonal therapy with anastrozole was scheduled for 10 years.
Eight years after surgery (during adjuvant hormonal therapy), her serum CA15-3 level increased (230 U/mL), but she had no symptoms. FDG-PET/CT was then done, and slight FDG accumulation was found in the pelvic peritoneum (SUVmax: 3.7), and peritoneal dissemination of breast cancer was suspected (Fig. 1). Pelvic MRI showed no abnormalities. Upper and lower endoscopic examinations also showed no abnormalities. The presence of primary gynecological and gastrointestinal cancers was denied. Since there was no confirmation of peritoneal dissemination, diagnostic laparoscopy was performed. Peritoneal dissemination was observed in the omentum, the mesentery, and the peritoneum of the pelvis, and a mesenteric nodule was biopsied (Figs. 2, 3). Pathological examination showed peritoneal dissemination of breast cancer, but the biological markers were different from the primary lesion: ER(−), PgR(−), and Her2:3 + (Figs. 4, 5). Additional immunostaining was performed, which was positive for GATA-3 and negative for TTF1, and the diagnosis of metastatic breast cancer was confirmed. Breast screening was performed to detect metachronous primary breast cancer, but there were no abnormalities.
Based on this result, perstuzumab, trastuzumab, and docetaxel combination therapy was started. Eight courses of perstuzumab therapy were completed, but peritoneal dissemination worsened, and she sometimes complained of stomach pain and diarrhea. Thus, the chemotherapy was changed to T-DM1. After several courses of T-DM1, her serum CA15-3 level decreased, and her systemic symptoms disappeared (Fig. 6).
Discussion
Bertozzi et al. reported that peritoneal carcinomatosis of breast cancer had a prevalence of 0.7%. Peritoneal carcinomatosis is significantly more common with a high-grade, invasive lobular carcinoma and advanced TNM stage. Despite a high serum CA15-3 level, the metastasis site might not be identified by general diagnostic imaging [1]. Modern imaging techniques have low accuracy for the diagnosis of peritoneal carcinomatosis. CT scans have size limitations that are important for the detection of lesions, particularly in the small intestinal wall. FDG-PET/CT has high false-positive rates due to tissue inflammation after systemic therapy, as well as false-negatives due to metabolic inactivity of dormant neoplastic cells after chemotherapy [2]. Of course it is necessary to rule out other cancers, especially digestive tract and gynecologic cancers.
In such cases, laparoscopic examination should be performed. In gastric cancer and pancreatic cancer, it is always performed to determine whether radical resection is indicated [3,4,5]. In gastric cancer, staging laparoscopy is performed if the patient has type 3 or 4 or bulky lymph node metastasis and para-aortic lymph node metastasis [3]. In such cases, positive peritoneal dissemination or positive lavage cytology is found in 42.7–53.4% of cases [6,7,8,9,10,11]. On the other hand, complications such as intestinal injuries occur in 0–2.9% of cases [6, 7, 11,12,13]. In pancreatic cancer, staging laparoscopy can not only diagnose peritoneal dissemination but also determine the indication for resection when combined with intraoperative laparoscopic ultrasonography [4, 5]. Overall survival after the diagnosis of breast cancer metastasis was shorter in women affected by peritoneal metastasis than in women with other metastases [1]. Therefore, it is necessary to detect peritoneal dissemination earlier.
Biopsy of metastatic lesions is very important, particularly in the case of relapses during adjuvant hormonal therapy, because biomarker changes may occur. Increasing HER2 expression levels from 0, 1 +, or 2 + in the primary lesion to 3 + or FISH score > 2 in the metastatic lesion was observed in 10% of metastatic breast cancer cases [14]. HER2 expression is very important information for systemic treatment, and if a change in HER2 expression has occurred but is not detected, inappropriate therapy may be given.
In conclusion, the diagnosis of peritoneal carcinomatosis is often difficult. In such cases, laparoscopy can easily confirm peritoneal carcinomatosis. Since the biomarkers of metastatic lesions may sometimes change, laparoscopic biopsy is very useful and helps optimize the patient’s treatment.
References
Bertozzi S, Londero AP, Cedolini C et al (2015) Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer. Springerplus 4:688
Fujii K, Watanabe R, Ando T et al (2017) Alterations in three biomarkers (estrogen receptor, progesterone receptor and human epidermal growth factor 2) and the Ki67 index between primary and metastatic breast cancer lesions. Biomed Rep 7:535–542
Fukagawa T (2019) Role of staging laparoscopy for gastric cancer patients. Ann Gastroenterol Surg 3:496–505
Sperlongano P, Pisaniello D, Piatto A et al (2006) The role of laparoscopy in pancreatic surgery. Front Biosci 11:2203–2205
Stefanidis D, Grove KD, Schwesinger WH et al (2006) The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol 17:189–199
Irino T, Sano T, Hiki N et al (2018) Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. Surg Endosc 32:268–275
Yamagata Y, Amikura K, Kawashima Y et al (2013) Staging laparoscopy in advanced gastric cancer: usefulness and issues requiring improvement. Hepatogastroenterology 60:751–755
Ishigami S, Uenosono Y, Arigami T et al (2014) Clinical utility of perioperative staging laparoscopy for advanced gastric cancer. World J Surg Oncol 12:350
Miki Y, Tokunaga M, Tanizawa Y et al (2015) Staging laparoscopy for patients with cM0, type 4, and large type 3 gastric cancer. World J Surg 39:2742–2747
Hosogi H, Shinohara H, Tsunoda S et al (2017) Staging laparoscopy for advanced gastric cancer: significance of preoperative clinicopathological factors. Langenbecks Arch Surg 402:33–39
Nakagawa S, Nashimoto A, Yabusaki H (2007) Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer. Gastric Cancer 10:29–34
Tsuchida K, Yoshikawa T, Tsuburaya A et al (2011) Indications for staging laparoscopy in clinical T4M0 gastric cancer. World J Surg 35:2703–2709
Shimizu H, Imamura H, Ohta K et al (2010) Usefulness of staging laparoscopy for advanced gastric cancer. Surg Today 40:119–124
Pasqual EM, Bertozzi S, Bacchetti S et al (2014) Preoperative assessment of peritoneal carcinomatosis in patients undergoing hyperthermic intraperitoneal chemotherapy following cytoreductive surgery. Anticancer Res 34:2363–2368
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Nakagawa, T., Oda, G., Kikuchi, A. et al. Peritoneal dissemination of breast cancer diagnosed by laparoscopy. Int Canc Conf J 10, 91–94 (2021). https://doi.org/10.1007/s13691-020-00456-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-020-00456-w